Aflibercept (Eylea(R))-Antibody screening - Qualitative

ELISA Genie Qualitative Antibodies to Aflibercept ELISA has been especially developed for the qualitative analysis of antibodies to aflibercept in serum and plasma samples. ELISA Genie Qualitative Antibodies to Aflibercept ELISA is optimized with Eylea(R).Aflibercept (Eylea(R)) Antibody screening - Qualitative ELISA Kit test principle Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Controls and samples (serum or plasma) are incubated in the microtiter plate coated with the drug aflibercept. After incubation, the wells are washed. Then, horseradish peroxidase (HRP) conjugated probe is added and binds to aflibercept antibodies captured by the drug aflibercept on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. Finally, the reaction is terminated with an acidic stop solution. The colour developed is proportional to the amount of aflibercept antibodies in the sample or controls. The results can be evaluated with using cutoff value. About Aflibercept (Eylea(R)) Antibody screening - Qualitative ELISA Kit: Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Aflibercept, as an ophthalmic agent, is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Compared to other anti-VEGF drugs like bevacizumab and ranibizumab, aflibercept has a higher binding affinity to VEGF-A. ELISA Genie kits can be used for drug level and anti-drug antibodies measurements.